Abstract

Review Article

OPEN and CLOSED state of SPIKE SARS-COV-2: relationship with some integrin binding. A biological molecular approach to better understand the coagulant effect

Luisetto M*, Khaled Edbey, Mashori GR, Yesvi AR and Latyschev OY

Published: 02 July, 2021 | Volume 5 - Issue 1 | Pages: 049-056

Related the physio-pathological process of COVID-19 disease it is interesting to focus to the aspect.

Played by interaction of Sars-Cov-2 protein with integrins of human epithelial pulmonary cell.

A bio molecular approach help in to deeply verify the involved factors and the results of this Activation RGD mediated.

Of Great interest also the relationship with some vaccine strategy followed by the various pharmaceutical industry.

The results of this work will be useful to think modification in some vaccine increasing the global safety and related some rare ADR.

Read Full Article HTML DOI: 10.29328/journal.abb.1001028 Cite this Article Read Full Article PDF

Keywords:

SPIKE; RGD; Integrin; Coagulation; Quantitative effect; Molecular approach

References

  1. Mei-Yue W, Zhao R, Li-Juan G, Xue-Fei G, De-Ping W, et al. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol. 2020; 10: 587269. PubMed: https://pubmed.ncbi.nlm.nih.gov/33324574/
  2. Pirone L, Del Gatto A, Di Gaetano S, Saviano M, Capasso D, et al. A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment. Front Mol Biosci. 2020; 7: 186. PubMed: https://pubmed.ncbi.nlm.nih.gov/32850973/
  3. Luan J, Lu Y, Gao S, Zhang L. A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2. 2020; 81: 318-356. PubMed: https://pubmed.ncbi.nlm.nih.gov/32283163/
  4. Calver J, Joseph C, John AE, Organ L, Fainberg H, et al. Understanding lung infection: back to basics. S31 The novel coronavirus SARS-CoV-2 binds RGD integrins and upregulates avb3 integrins in Covid-19 infected lungs. Thorax BMJ. 2021; 76: A22-A23.
  5. Zhang S, Liu Y, Wang X, Yang L, Li H, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020; 13: 120. PubMed: https://pubmed.ncbi.nlm.nih.gov/32887634/
  6. Allegra A, Innao V, Allegra AG, Musolino C. Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. Ann Hematol. 2020; 99: 1953-1965. PubMed: https://pubmed.ncbi.nlm.nih.gov/32671455/
  7. Liu Y, Yang Y, Zhang C, Huang F, Wang F, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020; 63: 364-374. PubMed: https://pubmed.ncbi.nlm.nih.gov/32048163/
  8. Smadja DM, Qun-Ying Y, Chocron R, Sanchez O, Louet AL. Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. Eur Respir J. 2021; 2100956. PubMed: https://pubmed.ncbi.nlm.nih.gov/33863748/
  9. Loo KY, Letchumanan V, Ser HL, Teoh SL, Law JWF, et al. COVID-19: Insights into Potential Vaccines. Microorganisms. 2021; 9: 605. PubMed: https://pubmed.ncbi.nlm.nih.gov/33804162/
  10. Grobbelaar LM, Venter C, Vlok M, Ngoepe M, Laubsche GJ, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. 202

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Figure 1

Figure 8

Figure 1

Figure 9

Figure 1

Figure 10

Figure 1

Figure 11

Similar Articles

Recently Viewed

  • A Case of Good Efficacy of Tolvaptan in a Patient with Markedly Enlarged Polycystic Kidney
    Masato Mizuta*, Tatsuya Suwabe, Akinari Sekine, Masayuki Yamanouchi, Hiroki Mizuno, Daisuke Ikuma, Eiko Hasegawa, Yuki Oba, Noriko Inoue, Makoto Fukuda, Motoaki Miyazono, Takehiko Wada, Naoki Sawa and Yoshifumi Ubara Masato Mizuta*, Tatsuya Suwabe, Akinari Sekine, Masayuki Yamanouchi, Hiroki Mizuno, Daisuke Ikuma, Eiko Hasegawa, Yuki Oba, Noriko Inoue, Makoto Fukuda, Motoaki Miyazono, Takehiko Wada, Naoki Sawa, Yoshifumi Ubara. A Case of Good Efficacy of Tolvaptan in a Patient with Markedly Enlarged Polycystic Kidney. J Clini Nephrol. 2024: doi: 10.29328/journal.jcn.1001135; 8: 100-102
  • Obstetric Renal Failure: Causes, Prognosis, and Evolution
    Tchich H*, Harmak K, Al-Firdaous I, Medkouri G, Mtioui N, Khayat SS, Zamd M and Benghanem M Tchich H*, Harmak K, Al-Firdaous I, Medkouri G, Mtioui N, Khayat SS, Zamd M, Benghanem M. Obstetric Renal Failure: Causes, Prognosis, and Evolution. J Clini Nephrol. 2024: doi: 10.29328/journal.jcn.1001133; 8: 091-094
  • Renal Adverse Reaction Secondary to Check-point Inhibitors in Metastatic Renal Cancer
    Marta Guerra Lacambra*, Miguel Angel Gonzalez Martinez, Vanesa García Chumillas and Francisco Gutierrez Tejero Marta Guerra Lacambra*, Miguel Angel Gonzalez Martinez, Vanesa García Chumillas, Francisco Gutierrez Tejero. Renal Adverse Reaction Secondary to Check-point Inhibitors in Metastatic Renal Cancer. J Clini Nephrol. 2024: doi: 10.29328/journal.jcn.1001130; 8: 076-077
  • Anatomo-clinical and Etiological Profile of Nephropathies Biopsied in the Nephrology Department of the Thies Regional Hospital (Senegal)
    Ameth Dieng*, Modou Ndongo, Rokhaya Fall, Mame Selly Diawara and Mouhamadou Moustapha Cissé Ameth Dieng*, Modou Ndongo, Rokhaya Fall, Mame Selly Diawara, Mouhamadou Moustapha Cissé. Anatomo-clinical and Etiological Profile of Nephropathies Biopsied in the Nephrology Department of the Thies Regional Hospital (Senegal). J Clini Nephrol. 2024: doi: 10.29328/journal.jcn.1001140; 8: 127-131
  • Hypercalcemia due to Elevated 1,25 dihydroxyvitamin D in Tophaceous Gout - Case Report and Literature Review
    Madhia Ahmad*, Sunnie Lee, Htay Htay Kyi, Shuwei Wang, Smitha Mahendrakar and Michael Yudd Madhia Ahmad*,Sunnie Lee,Htay Htay Kyi,Shuwei Wang,Smitha Mahendrakar,Michael Yudd. Hypercalcemia due to Elevated 1,25 dihydroxyvitamin D in Tophaceous Gout - Case Report and Literature Review. J Clini Nephrol. 2024: doi: 10.29328/journal.jcn.1001143; 8: 142-145

Read More

Most Viewed

Read More

Help ?